Premium
Results of a multicentre UK ‐wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting
Author(s) -
Eyre Toby A.,
Phillips Elizabeth H.,
Linton Kim M.,
Arumainathan Arvind,
Kassam Shireen,
Gibb Adam,
Allibone Suzanne,
Radford John,
Peggs Karl,
Burton Cathy,
Stewart Gillian,
LeDieu Rifca,
Booth Catherine,
Osborne Wendy L.,
Miall Fiona,
Eyre David W.,
Ardeshna Kirit M.,
Collins Graham P.
Publication year - 2017
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14898
Subject(s) - brentuximab vedotin , medicine , refractory (planetary science) , oncology , autologous stem cell transplantation , progression free survival , classical hodgkin lymphoma , retrospective cohort study , chemotherapy , lymphoma , surgery , cd30 , hodgkin lymphoma , physics , astrobiology
Summary Relapsed or refractory classical Hodgkin lymphoma ( cHL ) is associated with a poor outcome when standard chemotherapy fails. Brentuximab vedotin ( BV ) is an anti‐ CD 30 monoclonal antibody‐drug conjugate licensed for use at relapse after autologous stem cell transplant ( ASCT ) or following two prior therapies in those unsuitable for ASCT . There are limited data assessing the ability of BV to enable curative SCT . We performed a UK ‐wide retrospective study of 99 SCT ‐naïve relapsed/refractory cHL . All had received 2 prior lines and were deemed fit for transplant but had an insufficient remission to proceed. The median age was 32 years. Most had nodular sclerosis subtype, Eastern Cooperative Oncology Group performance status 0–1 and advanced stage disease. The median progression‐free survival ( PFS ) was 5·6 months and median overall survival ( OS ) was 37·2 months. The overall response rate was 56% (29% complete response; 27% partial response). 61% reached SCT : 34% immediately post‐ BV and 27% following an inadequate BV response but were salvaged and underwent deferred SCT . Patients consolidated with SCT had a superior PFS and OS to those not receiving SCT ( P < 0·001). BV is an effective, non‐toxic bridge to immediate SCT in 34% and deferred SCT in 27%. 39% never reached SCT with a PFS of 3·0 months, demonstrating the unmet need to improve outcomes in those unsuitable for SCT post‐ BV .